Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses IPSC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IPSC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chad Cowan | $559,532 | $0 | $398,329 | $8,327 | $201,007 | $0 | $0 | $1,167,015 |
| Chief Scientific Officer | ||||||||
| Adrienne Farid | 333,348 | 0 | 71,120 | 51,240 | 0 | 0 | 533,515 | 989,403 |
| Former Chief Development Officer | ||||||||
| Gregory Russotti | 559,650 | 0 | 71,120 | 51,240 | 226,658 | 0 | 3,652 | 912,320 |
| Chief Technology and Manufacturing Officer and former Interim President and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Chad Cowan | $1,167,015 | — | — | — |
| Adrienne Farid | 989,403 | 1,417,304 | — | −427,901 |
| Gregory Russotti | 912,320 | 1,487,604 | — | −575,284 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Chad Cowan | RSU | 55,782 | — | $55,503 |
| Chad Cowan | RSU | 762,543 | — | 758,730 |
| Gregory Russotti | RSU | 120,000 | — | 119,400 |
| Chad Cowan | RSU | 19,500 | — | 19,402 |
| Gregory Russotti | RSU | 13,500 | — | 13,433 |
| Gregory Russotti | Option | 2,188 | 13.15 | — |
| Gregory Russotti | Option | 51,044 | 4.64 | — |
| Gregory Russotti | Option | 106,256 | 2.91 | — |
| Gregory Russotti | Option | 82,131 | 5.32 | — |
| Gregory Russotti | Option | 120,000 | 0.6 | — |
| Adrienne Farid | Option | 168,655 | 1.03 | — |
| Adrienne Farid | Option | 15,462 | 1.75 | — |
| Adrienne Farid | Option | 207,649 | 7.27 | — |
| Adrienne Farid | Option | 91,872 | 13.15 | — |
| Adrienne Farid | Option | 79,390 | 4.64 | — |
| Adrienne Farid | Option | 48,664 | 5.32 | — |
| Chad Cowan | Option | 316,096 | 1.65 | — |
| Chad Cowan | Option | 19,500 | 0.6 | — |
The compensation of our NEOs generally consists of base salary, annual cash incentive opportunities, long-term incentive compensation in the form of equity awards, and other benefits. Equity-based incentive awards are designed to align the interests of our stockholders with those of our NEOs.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $44,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Century Therapeutics | 2025 | Chad Cowan | $559,532 | $398,329 | $8,327 | $201,007 | $1,167,015 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Chad Cowan | DEF 14A | 2026-04-27 | 0001104659-26-049489 | Section “SUMMARY COMPENSATION TABLE”. As printed: 1,167,015. Filing ↗machine: r7 · c26 · span 538937–538946 |
| 2 | Section 01, Adrienne Farid | DEF 14A | 2026-04-27 | 0001104659-26-049489 | Section “SUMMARY COMPENSATION TABLE”. As printed: 989,403. Filing ↗machine: r5 · c26 · span 530229–530236 |
| 3 | Section 01, Gregory Russotti | DEF 14A | 2026-04-27 | 0001104659-26-049489 | Section “SUMMARY COMPENSATION TABLE”. As printed: 912,320. Filing ↗machine: r3 · c26 · span 521444–521451 |
| 4 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 5 | Century Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001104659-26-049489 | CEO total compensation as printed in Century Therapeutics's own proxy. As printed: 1,167,015. Filing ↗machine: r7 · c26 · span 538937–538946 |